Where CymaBay Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 14 analysts have published their opinion on CymaBay Therapeutics (NASDAQ:CBAY) stock. The majority of these analysts are bullish, with an average price target of $22.93, indicating a potential upside from the current price of $16.55. The average price target has increased by 29.77% from the previous average of $17.67.
November 06, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts are bullish on CymaBay Therapeutics (NASDAQ:CBAY) with an average price target of $22.93, indicating a potential upside from the current price of $16.55.
The bullish sentiment from analysts, coupled with an average price target that is significantly higher than the current price, suggests a potential upside for CymaBay Therapeutics' stock in the short term. This could lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100